Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Capital Expenditures (2020 - 2022)

Guided Therapeutics' Capital Expenditures history spans 8 years, with the latest figure at $3000.0 for Q4 2022.

  • For Q4 2022, Capital Expenditures fell 25.0% year-over-year to $3000.0; the TTM value through Sep 2023 reached $3000.0, down 90.62%, while the annual FY2022 figure was $31000.0, 121.43% up from the prior year.
  • Capital Expenditures for Q4 2022 was $3000.0 at Guided Therapeutics, up from -$3000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $17000.0 in Q2 2022 and bottomed at -$3000.0 in Q3 2022.
  • The 3-year median for Capital Expenditures is $4000.0 (2021), against an average of $5111.1.
  • The largest YoY upside for Capital Expenditures was 1300.0% in 2022 against a maximum downside of 160.0% in 2022.
  • A 3-year view of Capital Expenditures shows it stood at $1000.0 in 2020, then soared by 300.0% to $4000.0 in 2021, then fell by 25.0% to $3000.0 in 2022.
  • Per Business Quant, the three most recent readings for GTHP's Capital Expenditures are $3000.0 (Q4 2022), -$3000.0 (Q3 2022), and $17000.0 (Q2 2022).